Skip to main content
Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
12.39
-0.13 (-1.04%)
Jan 17, 2025, 4:00 PM EST - Market closed

Myriad Genetics Revenue

Myriad Genetics had revenue of $213.30M in the quarter ending September 30, 2024, with 11.15% growth. This brings the company's revenue in the last twelve months to $823.60M, up 12.15% year-over-year. In the year 2023, Myriad Genetics had annual revenue of $753.20M with 11.03% growth.

Revenue (ttm)
$823.60M
Revenue Growth
+12.15%
P/S Ratio
1.35
Revenue / Employee
$305,037
Employees
2,700
Market Cap
1.13B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023753.20M74.80M11.03%
Dec 31, 2022678.40M-12.20M-1.77%
Dec 31, 2021690.60M133.60M23.99%
Dec 31, 2020557.00M-81.60M-12.78%
Jun 30, 2020638.60M-212.50M-24.97%
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 87.70B
Merck & Co. 63.17B
AbbVie 55.53B
AstraZeneca 51.21B
Novartis AG 49.94B
Thermo Fisher Scientific 42.37B
Abbott Laboratories 41.22B
Revenue Rankings

MYGN News

More News